Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
57

Summary

Conditions
  • Adrenocortical Carcinoma
  • Genitourinary Cancer
  • High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
  • Non-adenocarcinoma Prostate Cancer
  • Non-urothelial Bladder
  • Non-urothelial Upper Tract
  • Penile Cancer
  • Refractory Germ-cell
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the combination of drugs works in treating a specific disease. "Investigational" means that the drugs are being studied. The FDA (the U.S. Food and...

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the combination of drugs works in treating a specific disease. "Investigational" means that the drugs are being studied. The FDA (the U.S. Food and Drug Administration) has not approved nivolumab in combination with ipilimumab for this specific disease but the combination is approved for use in melanoma patients. In this research study, the investigators are... Investigating the response of the participant's cancer to treatment with nivolumab plus ipilimumab, Assessing the safety of treatment with nivolumab and ipilimumab and Evaluating response and resistance to treatment by looking at the participant's tumor tissue and blood for markers to predict response and resistance to therapy.

Tracking Information

NCT #
NCT03333616
Collaborators
Bristol-Myers Squibb
Investigators
Principal Investigator: Bradley A McGregor, MD Dana-Farber Cancer Institute